Oncolytics Biotech Announces Updated Phase 1/2 GOBLET Study Data for Pelareorep in Anal Cancer

Article summary

Oncolytics Biotech reported updated data from Cohort 4 of its Phase 1/2 GOBLET study, showing strong durability and survival in patients with second-line or later squamous cell anal cancer treated with pelareorep and atezolizumab.